- Market News
Cambrex to expand generic API R&D capabilities at Milan, Italy site12 Jun 2018
Company to increase the number of generic APIs in the company's development pipeline.
Cambrex will expand R&D capabilities at its site in Paullo, Milan, Italy. The investment will fund the construction of a new 150-m² R&D laboratory and the recruitment of additional scientists to increase the number of generic APIs in the company’s development portfolio.
The new laboratory will include 14 fume hoods and will combine both chemistry and analytical development capabilities, with the installation of glass-lined reactors, as well as analytical instruments including multiple high and ultra-performance liquid chromatography, and gas chromatography systems. The building work is estimated to be completed by the end of 2018, allowing installation and validation of the analytical instruments to take place in Q1 2019.
“The generic API industry is growing due to the continued expiry of product patents, which results in the constant flow of new generic entrants to the market,” commented Aldo Magnini, Managing Director, Cambrex Milan. “The new laboratory will increase the number of programs we can be active in at any one time, allowing us to expand our portfolio of generic products.”
Cambrex currently manufactures over 70 generic APIs, which are produced to cGMP standards and the Milan site comprises seven production departments, supported by a pilot plant, kilo-scale plant, and development and analytical laboratories.
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation